Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioLineRx in $270 Million Deal for China Rights for Stem Cell Mobilizer

publication date: Oct 31, 2023

BioLineRx, an Israeli biotech, out-licensed China rights to motixafortide, a stem cell mobilizer, to Guangzhou Gloria Biosciences in a $280 million agreement. One month ago, BioLineRx was approved to launch Aphexda™ (motixafortide) in the US in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells for collection and autologous re-transplantation in multiple myeloma patients. It also plans to start trials of motixafortide in patients with sickle cell disease. In 2021, GloriaBio was approved for China marketing of YuTuo® (zimberelimab), a PD-1 inhibitor, for classical Hodgkin’s lymphoma. More details....

Stock Symbols: (NSDQ/TASE: BLRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital